117 Broadway
Unit 4
Nedlands, WA 6009
Australia
61 8 9329 3396
https://argenica.com.au
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Liz Dallimore B.Sc., M.B.A., Ph.D. | CEO, MD & Director | 324.12k | N/A | N/A |
Ms. Emma Waldon | CFO & Company Secretary | N/A | N/A | 1976 |
Prof. Bruno Philip Meloni | Chief Scientific Officer | N/A | N/A | N/A |
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. Argenica Therapeutics Limited was incorporated in 2019 and is headquartered in Nedlands, Australia.
Argenica Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.